エナンタ・ファーマシューティカルズ
Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q3 | -0.67 | $14M | -$10M |
| 2026 Q2 | -0.45 | $17M | -$7M |
| 2025 Q1 | -0.42 | $19M | -$12M |
| 2025 Q4 | -0.87 | $15M | -$8M |
| 2025 Q3 | -0.86 | $18M | $17M |
| 2025 Q2 | -1.06 | $15M | -$16M |
| 2024 Q1 |
| -1.05 |
| $17M |
| -$26M |
| 2024 Q4 | -1.36 | $15M | -$19M |